Cardiovascular disease risk reduction by raising HDL cholesterol - current therapies and future opportunities

Oxidized phospholipid content destabilizes the structure of reconstituted high density lipoprotein particles and changes their function

(2012) Subhabrata Kar et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A

(2012) Markus Tölle et al.   CARDIOVASCULAR RESEARCH

Is niacin ineffective? Or did AIM-HIGH miss its target?

(2012) S. J. NICHOLLS   CLEVELAND CLINIC JOURNAL OF MEDICINE

Purified human paraoxonase-1 interacts with plasma membrane lipid rafts and mediates cholesterol efflux from macrophages

(2012) Hicham Berrougui et al.   FREE RADICAL BIOLOGY AND MEDICINE

Impact of Mifepristone, a Glucocorticoid/Progesterone Antagonist, on HDL Cholesterol, HDL Particle Concentration, and HDL Function

(2012) Stephanie T. Page et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Tributyltin chloride induces ABCA1 expression and apolipoprotein A-I-mediated cellular cholesterol efflux by activating LXRalpha/RXR

(2011) Hongyan Cui et al.   BIOCHEMICAL PHARMACOLOGY

A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR-/- mice

(2011) Dacheng Peng et al.   BRITISH JOURNAL OF PHARMACOLOGY

Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome

(2011) Barbara C Hansen et al.   Cardiovascular Diabetology

Imaging Biomarkers in Atherosclerosis Trials

(2011) Jean-Claude Tardif et al.   Circulation-Cardiovascular Imaging

Uremia Alters HDL Composition and Function

(2011) M. Holzer et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial

(2011) Zahi A Fayad et al.   LANCET

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages

(2010) Lesley E. Smythies et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

LXRα regulates human CETP expression in vitro and in transgenic mice

(2010) Shoko Honzumi et al.   ATHEROSCLEROSIS

Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F1B hamsters

(2010) Rai Ajit K. Srivastava   ATHEROSCLEROSIS

Novel tetrahydrochinoline derived CETP inhibitors

(2010) Carsten Schmeck et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors

(2010) Aihua Wang et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels

(2010) JWA van der Hoorn et al.   BRITISH JOURNAL OF PHARMACOLOGY

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study

(2010) Alexander Tenenbaum et al.   Cardiovascular Diabetology

High-density lipoproteins, platelets and the pathogenesis of atherosclerosis

(2010) Jerzy-Roch Nofer et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial

(2010) Evan A. Stein et al.   EUROPEAN HEART JOURNAL

Lipoprotein(a) as a cardiovascular risk factor: current status

(2010) Børge G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

The versatility of HDL: a crucial anti-inflammatory regulator

(2010) Marcus D. Säemann et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Niacin's role in the statin era

(2010) Erica L Brooks et al.   EXPERT OPINION ON PHARMACOTHERAPY

Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein

(2010) Jonathan D. Smith   Journal of Clinical Lipidology

Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL

(2010) John S. Millar et al.   JOURNAL OF LIPID RESEARCH

The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?: Fig. 1.

(2010) Menno Vergeer et al.   JOURNAL OF LIPID RESEARCH

A Selective Peroxisome Proliferator-Activated Receptor   Agonist, CP-900691, Improves Plasma Lipids, Lipoproteins, and Glycemic Control in Diabetic Monkeys

(2010) J. D. Wagner et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

RVX-208

(2010) Dana Bailey et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis)

(2010) Todd C. Villines et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

High-Density Lipoprotein and Coronary Heart Disease

(2010) Pradeep Natarajan et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial

(2010) Paul M Ridker et al.   LANCET

Responding to an FDA Warning — Geographic Variation in the Use of Rosiglitazone

(2010) Nilay D. Shah et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

(2010) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome

(2009) Gregory G. Schwartz et al.   AMERICAN HEART JOURNAL

Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib

(2009) Christopher P. Cannon et al.   AMERICAN HEART JOURNAL

Lessons Learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial

(2009) Philip Barter   AMERICAN JOURNAL OF CARDIOLOGY

Safety and Tolerability of Dalcetrapib††Conflicts of interest: Dr. Stein has received grants for studies of lipid-modifying agents, has received consulting fees and honoraria for professional input regarding agents to modify lipid profile, and/or has delivered lectures for the American Association for Clinical Chemistry, Washington, District of Columbia; Abbott Laboratories, Abbott Park, Illinois; AstraZeneca, Wilmington, Delaware; the United States Food and Drug Administration, Washington, District of Columbia; F. Hoffmann-La Roche Ltd., Basel, Switzerland; Isis Pharmaceuticals, Inc., Carlsbad, California; Merck & Co., Whitehouse Station, New Jersey; the National Lipid Association, Jacksonville, Florida; Novartis International AG, Basel Switzerland; Reliant Pharmaceuticals, Inc., Liberty Corner, New Jersey; Daiichi Sankyo Co., Ltd., Tokyo, Japan; Schering-Plough Corporation, Kenilworth, New Jersey; Takeda Pharmaceutical Company Ltd., Osaka, Japan; and Wyeth, Madison, New Jersey. Dr. Stroes has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. and Novartis International AG. Dr. Steiner has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd.; Solvay, Brussels, Belgium; Ethypharm S.A., Saint-Cloud, France; and Merck Frosst Canada Ltd. (Kirkland, Quebec, Canada)/Schering-Plough Corporation. Dr. Buckley has received research grants from AstraZeneca; Merck Sharp & Dohme, Dublin, Ireland; and Pfizer, Inc., New York, New York. Dr. Buckley has received honoraria and consulting fees and/or delivered lectures for AstraZeneca; Bristol-Myers Squibb, New York, New York; F. Hoffmann-La Roche Ltd.; Novartis International AG; Pfizer, Inc.; and Sanofi-Aventis, Paris, France. Dr. Capponi has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. Dr. Burgess is an employee of Hoffmann-La Roche Inc., Nutley, New Jersey. Drs. Niesor and Kallend are employees of F. Hoffmann-La Roche Ltd. Dr. Kastelein has received research grants, honoraria, or consulting fees for professional input and/or has delivered lectures for Pfizer, Inc.; Merck Sharp & Dohme; F. Hoffmann-La Roche Ltd.; Novartis International AG; Isis Pharmaceuticals, Inc.; Kowa Pharmaceutical Company Ltd., Nagoya, Japan; Schering-Plough Corporation; and AstraZeneca.

(2009) Evan A. Stein et al.   AMERICAN JOURNAL OF CARDIOLOGY

Novel Targets that Affect High-Density Lipoprotein Metabolism: The Next Frontier

(2009) Michael H. Davidson et al.   AMERICAN JOURNAL OF CARDIOLOGY

Effect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review

(2009) Samuel Abourbih et al.   AMERICAN JOURNAL OF MEDICINE

Structure and Function of HDL Mimetics

(2009) Mohamad Navab et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The 5A Apolipoprotein A-I Mimetic Peptide Displays Antiinflammatory and Antioxidant Properties In Vivo and In Vitro

(2009) Fatiha Tabet et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Dysfunctional HDL as a Diagnostic and Therapeutic Target

(2009) Jonathan D. Smith   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

On the mechanism for PPAR agonists to enhance ABCA1 gene expression

(2009) Masaki Ogata et al.   ATHEROSCLEROSIS

Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: A randomized placebo-controlled study

(2009) Ioannis Andreou et al.   ATHEROSCLEROSIS

Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis

(2009) Eric Bruckert et al.   ATHEROSCLEROSIS

Synthesis and evaluation of novel α-heteroaryl-phenylpropanoic acid derivatives as PPARα/γ dual agonists

(2009) Agustin Casimiro-Garcia et al.   BIOORGANIC & MEDICINAL CHEMISTRY

The dual PPARα/γ agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice

(2009) JWA Van Der Hoorn et al.   BRITISH JOURNAL OF PHARMACOLOGY

Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia

(2009) Helen Vosper   BRITISH JOURNAL OF PHARMACOLOGY

Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy

(2009) Sajoscha A. Sorrentino et al.   CIRCULATION

Both the Peroxisome Proliferator-Activated Receptor δ Agonist, GW0742, and Ezetimibe Promote Reverse Cholesterol Transport in Mice by Reducing Intestinal Reabsorption of HDL-Derived Cholesterol

(2009) François Briand et al.   CTS-Clinical and Translational Science

Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels

(2009) Derek J Hausenloy et al.   CURRENT OPINION IN CARDIOLOGY

The mechanism and mitigation of niacin-induced flushing

(2009) V. S. Kamanna et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Major Lipids, Apolipoproteins, and Risk of Vascular Disease

(2009) The Emerging Risk Factors Collaboration*   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database

(2009) Philip J. Barter et al.   JOURNAL OF LIPID RESEARCH

Design, Synthesis, and Biological Evaluation of (2R,αS)-3,4-Dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl]-α-(trifluoromethyl)-1(2H)-quinolineethanol as Potent and Orally Active Cholesteryl Ester Transfer Protein Inhibitor

(2009) Gee-Hong Kuo et al.   JOURNAL OF MEDICINAL CHEMISTRY

Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

(2009) Robert R Henry et al.   LANCET

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

(2009) Paul M Ridker et al.   LANCET

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

(2008) Daniel Bloomfield et al.   AMERICAN HEART JOURNAL

Relation of Clinical Benefit of Raising High-Density Lipoprotein Cholesterol to Serum Levels of Low-Density Lipoprotein Cholesterol in Patients With Coronary Heart Disease (from the Bezafibrate Infarction Prevention Trial)

(2008) Ilan Goldenberg et al.   AMERICAN JOURNAL OF CARDIOLOGY

Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice

(2008) José W.A. van der Hoorn et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

HDL-Associated Lysosphingolipids Inhibit NAD(P)H Oxidase-Dependent Monocyte Chemoattractant Protein-1 Production

(2008) Markus Tölle et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Liver X Receptors (LXR) as Therapeutic Targets in Dyslipidemia

(2008) Jerzy Bełtowski   Cardiovascular Therapeutics

Combined Statin and Niacin Therapy Remodels the High-Density Lipoprotein Proteome

(2008) Pattie S. Green et al.   CIRCULATION

Rosiglitazone modifies HDL structure and increases HDL-apo AI synthesis and catabolic rates

(2008) Elizabeth Carreón-Torres et al.   CLINICA CHIMICA ACTA

PAR-5359, a well-balanced PPARα/γ dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo

(2008) Mi-Kyung Kim et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins

(2008) A. R. Tall   JOURNAL OF INTERNAL MEDICINE

Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients

(2008) LeAnne T. Bloedon et al.   JOURNAL OF LIPID RESEARCH

Novel Peroxisome Proliferator-Activated Receptor   Agonists Lower Low-Density Lipoprotein and Triglycerides, Raise High-Density Lipoprotein, and Synergistically Increase Cholesterol Excretion with a Liver X Receptor Agonist

(2008) R. Mukherjee et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Beyond High-Density Lipoprotein Cholesterol Levels

(2008) Emil M. deGoma et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Is raising HDL a futile strategy for atheroprotection?

(2008) Tisha Joy et al.   NATURE REVIEWS DRUG DISCOVERY

Alterations in cell adhesion molecules and other biomarkers of cardiovascular disease in patients with metabolic syndrome

(2007) Leonardo Gómez Rosso et al.   ATHEROSCLEROSIS

Nicotinic acid: an old drug with a promising future

(2007) E T Bodor et al.   BRITISH JOURNAL OF PHARMACOLOGY